Stranica 1 iz 83 rezultatima
UNASSIGNED
Duodenal metastasis of testicular cancer is an uncommon condition in clinical practice. Here, we have reported a case of this nature.
UNASSIGNED
Testicular cancers are among the most seen cancer types among young men. Metastasis of testicular cancer generally occurs through hematogenous
Fewer than 5% of patients with metastatic testicular cancer present with gastrointestinal involvement. Even rarer is testicular metastasis to the duodenum. We present the case of a previously healthy 26-year-old man who had symptomatic gastrointestinal bleeding caused by metastatic testicular
Thirty-six patients with advanced non-seminomatous germ-cell testicular tumours and two patients with advanced seminomas were treated with cisplatin-containing combination chemotherapy. Thirty-four patients received cisplatin 100 mg/m2 iv, vinblastine 0.3 mg/kg iv and bleomycin 30 mg iv (PVB) and
Eleven patients with testicular cancer, either relapsing after or refractory to cisplatin-based chemotherapy, underwent salvage chemotherapy with high-dose carboplatin (800 mg/m2 on day 1) and high-dose etoposide (500 mg/m2 on days 1, 3 and 5). A total of 21 courses were administered. The major
We describe our experience with BEP (bleomycin, etoposide, cisplatin) therapy as chemotherapy for testicular tumors in 11 patients. Eight were non-seminomatous testicular cancer patients and 3 were seminoma patients. Three of 8 non-seminomatous testicular cancer patients had no evident metastasis
Fifteen patients with metastatic non-seminomatous germ-cell tumours with good prognosis were treated with carboplatin-etoposide-bleomycine chemotherapy. Patients were followed-up from 8 to 56 months (median 32 months). In 13 patients there was no evidence of the disease and in 2 patients recurred,
The linear-analogue self-assessment (LASA) technique was used to assess acute toxicity and other pertinent attributes relative to quality of life (QL) in patients with advanced testicular cancer who were entered into chemotherapy trials with either velban, Actinomycin-D, bleomycin, cisplatin, and
Advanced testicular tumors in 34 patients were treated by combination chemotherapy with bleomycin, vinblastine, vincristine, cis platinum and actinomycin D. The therapy was divided into 3 phases: 1) induction, 2) consolidation and 3) maintenance. Induction lasted 4 weeks and consisted of 420 mg.
A combination regimen consisting of cisplatin, bleomycin, and vinblastine was evaluated in 86 patients with metastatic testicular tumors. Prior therapy included surgical resection of primary tumor (84 patients), radiotheapy (21 patients), chemotherapy (33 patients). Thirteen patients received prior
The combination of cisplatin, etoposide and bleomycin (PEB) is considered to be the standard therapy in adjuvant situations for non-seminomas with vascular invasion (1-2 cycles) and for metastatic seminomas as well as non-seminomas (3-4 cycles). In the case of contraindications to bleomycin - above
The role of antiemetics is invaluable in allowing cancer patients to complete, otherwise possibly intolerable, chemotherapy. In the Perugia Consensus Conference it was decided that the recommended antiemetic regimen in the prevention of acute emesis induced by a single high, low and repeated doses
Ondansetron is a selective 5-HT3 antagonist with significant antiemetic properties in patients receiving cytotoxic chemotherapy. Patients who had suffered severe vomiting on carboplatin alone (23 patients with ovarian carcinoma) or in combination (two patients with testicular cancer) despite
OBJECTIVE
The aims of this study were to assess the safety and antiemetic efficacy of multiple-day dosing of palonosetron plus dexamethasone in patients receiving highly emetogenic multiple-day cisplatin-based chemotherapy for germ cell tumors.
METHODS
Forty-one men undergoing 5-day cisplatin-based
OBJECTIVE
The objective of this study was to estimate the cost of antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in daily practice in Japan.
METHODS
This was a retrospective observational study using medical records. Eligible patients were those with bladder or testicular
We report a case of congenital adrenal hyperplasia (CAH) occurring in a 21-year-old man. He was found to have 21-hydroxylase deficiency shortly after birth in search for the cause of vomiting and adrenal insufficiency, and placed on steroid therapy. He had an uneventful childhood with normal onset